Accumulating evidence demonstrates that lncRNAs play important roles in regulating gene expression and are involved in various pathological processes. In the present study, we screened the lncRNAs profile in clear cell renal cell carcinoma (ccRCC) from The Cancer Genome Atlas (TCGA) database, and got linc00152, a differentially expressed lncRNA that haven't been reported in ccRCC. To further explore its role in ccRCC, the level of Linc00152 was detected in 77 paired ccRCC tissues and renal cancer cell lines by qRT-PCR, and its association with overall survival was assessed by statistical analysis. Linc00152 expression was significantly up-regulated in cancerous tissues and cell lines compared with normal counterparts, and high Linc00152 expression was closely associated with advanced TNM stage. Moreover, Linc00152 was found to be able to serve as an independent predictor of overall survival. Further experiments demonstrated that overexpression of Linc00152 can significantly promote cell proliferation and invasion, inhibit cell cycle arrest in G1 phase and dramatically decrease apoptosis in both 786O and Caki-2 cell lines, whereas the opposite results were observed with attenuated Linc00152 expression. Our data suggest that Linc00152 is a novel molecule involved in ccRCC progression as well as a potential prognostic biomarker and therapeutic target.
American journal of cancer research. 2016 Jan 15*** epublish ***
Yong Wu, Cong Tan, Wei-Wei Weng, Yu Deng, Qiong-Yan Zhang, Xiao-Qun Yang, Hua-Lei Gan, Tao Wang, Pei-Pei Zhang, Mi-Die Xu, Yi-Qin Wang, Chao-Fu Wang
Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Fudan University Shanghai Cancer CenterShanghai, China; Department of Oncology, Shanghai Medical College, Fudan UniversityShanghai, China; Institute of Pathology, Fudan UniversityShanghai 200032, China., Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University Shanghai 200011, China., Department of Pathology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai 20025, China.